AI
CADL icon

Atom Investors’s Candel Therapeutics CADL Stock Holding History

Atom Investors’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14,873
Closed -$103K – 508
2024
Q3 		$103K Buy
+14,873
New +$92.4K 0.01% 437

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $456M AUM 49.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Atom Investors's CADL Position: Q4 2024 in Review

Atom Investors sold out of Candel Therapeutics (CADL) in Q4 2024, closing a stake of 14,873 shares — an estimated $103K sold.

Atom Investors first reported a position in CADL in Q3 2024 and held it in 1 quarter. The position peaked at $103K in Q3 2024. 71 funds tracked by Wall St. Rank hold CADL as of Q4 2024.

  • Atom Investors reported no remaining Candel Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Atom Investors sold 14,873 Candel Therapeutics shares in Q4 2024, an estimated $103K.
  • Atom Investors first reported a position in Candel Therapeutics in Q3 2024 and held it in 1 quarter.
  • Atom Investors's Candel Therapeutics position peaked at $103K in Q3 2024.
  • 71 funds tracked by Wall St. Rank held Candel Therapeutics as of Q4 2024.

Based on Atom Investors's 13F filing for Q4 2024, filed 14 Feb 2025.